Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “BURMA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources
PubMed1973

Late lepromin reaction in untreated patients with indeterminate leprosy under 21 years old in Burma.

Studies on lepromin reactivity in indeterminate (I) leprosy have usually been carried out among patients in whom the disease appeared 1 or more years before testing. This may result in misleading findings because a high proportion of patients, probably those showing moderate or strong lepromin reactions, seem to progress to the tuberculoid pole of leprosy in a relatively short time (<1 year), and in many the lesions heal spontaneously. The object of the present study was to determine the frequency and intensity of late lepromin reactions (macroscopic readings) in untreated I patients aged under 21 years who had had the disease for less than 1 year. Of 209 patients tested with lepromin containing 160 x 10(6) bacilli/ml only a small proportion ( not equal 7%) showed a negative or doubtful lepromin reaction, while 61.5% were 2+ and 3+ reactors. These findings indicate that a favourable outcome may be expected in most I cases in the trial area.

Adult↗
PubMed1974

BCG vaccination of children against leprosy: nine-year findings of the controlled WHO trial in Burma.

The leprosy incidence rates so far in the vaccinated and unvaccinated children aged 5-9 and 10-14 years are similar. The BCG-vaccinated children aged 0-4 years at intake had an incidence rate lower than that of children in the control group. BCG vaccination did not protect household contacts or children aged 5-14 years not exposed in the household, and did not influence the distribution of the forms of leprosy in the cases detected. The lepromin reaction in relation to the age at intake was consistently stronger in the vaccinated children than in those of the control group; the younger the age group the more pronounced was the difference, which was only slight in the age group 10-14 years at intake. If the results of the late lepromin reaction are related to the age at onset (when the children are older than at intake), the differences between the BCG and the control groups tend to decrease. It does not seem that the BCG-vaccinated children suffer from a less serious form of leprosy than the nonvaccinated children (most of them nonreactors to tuberculin).

Adolescent↗
PubMed1974

Clinical and laboratory studies on haemorrhagic fever in Burma, 1970-72.

This three-year serologic study of 2 060 children with a clinical diagnosis of haemorrhagic fever, who were admitted to the Children's Hospital and other hospitals in Rangoon, has shown that the etiology of the illness was multiple. Of all these patients, 347 (16.8%) had a dengue infection (96 with primary and 251 with secondary dengue infections), 510 (24.7%) had chikungunya infections, 55 (2.7%) had simultaneous chikungunya and dengue, 263 (12.8%) had influenza A infections, 62 (3.0%) had influenza B, 12 (0.6%) had measles, and there were 811 (39.4%) for whom no etiology could be established. Epidemiological and clinical features and laboratory findings are discussed. Evidence is presented for human infections with all four types of denguevirus in Rangoon.

Child↗
PubMed1982

Single-dose treatment of falciparum malaria with mefloquine: field studies with different doses in semi-immune adults and children in Burma.

Different doses of mefloquine (20 and 30 mg/kg of body weight in children, and 750 and 1000 mg in adults) were tested in controlled clinical trials in 89 children and 60 adults who were semi-immune carriers of Plasmodium falciparum. There was no significant difference in the efficacy of the two doses, either in the children or in the adults. An RI-type resistance was found in 1 adult, when recrudescence occurred on day 7, and in 4 children, who showed recrudescence on day 14. In all 5 patients, spontaneous disappearance of parasites was observed at further parasitological checks, thus indicating that mefloquine has a prolonged action. One patient who vomited after taking the drug was successfully retreated with mefloquine on day 14.Nausea, giddiness, and vomiting are the three symptoms most frequently attributed to mefloquine. The incidence of nausea and giddiness was similar in both dosage groups, but the adults in the higher dosage group had a significantly higher frequency of vomiting than those in the low-dose group.In view of the rapid and reliable action of a single dose, mefloquine seems to be the drug of choice for treatment of cases of falciparum malaria that are resistant to 4-aminoquinolines and to sulfonamide-pyrimethamine combinations. A dose of 20 mg per kg of body weight for children and 750 mg for adults is sufficient for treatment of semi-immune persons.

Adolescent↗